BCG
BCG-medac, powder and solvent for suspension for intravesical use

BCG (Bacillus Calmette Guérin) is indicated for the treatment of non-invasive urothelial bladder carcinoma:
- curative treatment of carcinoma in situ
- prophylactic treatment of recurrence of :
- urothelial carcinoma limited to mucosa :
- Ta G1-G2 if multifocal and/or recurrent tumour
- Ta G3
- urothelial carcinoma in lamina propria but not the muscular of the bladder (T1)
- carcinoma in situ
- urothelial carcinoma limited to mucosa :
The active ingredient is BCG (Bacillus Calmette Guérin) bacteria seed RIVM derived from seed 1173-P2 2 x 108 to 3 x 109 viable units
This product is available in the following presentations:
- Powder & Solution for suspension for intravesical use in 50ml bag
It is available in the Republic of Ireland from Fannin Ltd in partnership with Medac. (This link will take you to a non-Fannin Ltd. website. Fannin Ltd. does not recommend, endorse or accept liability for sites controlled by third-parties).
For a copy of the SPC please click here.
Method of Sale: POM
PA Number: PA 0623/004/001
MAH Holder: medac Gesellschaft für klinische Spezialpräparate mbH Theaterstr. 6 22880 Wedel Germany
For additional information please contact our medical information department at medical@dccvital.com or via phone on 01 2907000
Additional information available on request.
Date of preparation: July 2018
IE2018/086/00